At 7.0% CAGR, the Middle East & Africa Lung Cancer Screening Market is projected to be worth US$ 30.11 million by 2030, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa lung cancer screening market was valued at US$ 17.52 million in 2022 and is expected to reach US$ 30.11 million by 2030, registering a CAGR of 7.0% from 2022 to 2030. Rising lung cancer incidences is the critical factor attributed to the Middle East & Africa lung cancer screening market.

Lung cancer is among one of the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis of lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are prompted to undergo routine checkups to detect the formation of cancerous growth in their lungs.

The socioeconomic conditions, healthcare infrastructure, and methods used to provide healthcare vary greatly throughout the Middle Eastern and African nations. The prevalence of lung cancer is extremely high in these nations and is expected to keep rising in the near future. Thus, the rising incidences of lung cancer are contributing to the initiation of lung cancer screening programs, which drive market growth.

On the contrary, high cost of lung cancer screening hampers the Middle East & Africa lung cancer screening market. 

Based on cancer type, the Middle East & Africa lung cancer screening market is segmented into non–small cell lung cancer (NSCLC) and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held 82.5% share of Middle East & Africa lung cancer screening market in 2022, amassing US$ 14.46 million. It is projected to garner US$ 24.49 million by 2030 to expand at 6.8% CAGR during 2022–2030.

Based on technology, the Middle East & Africa lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. The chest X-ray segment held 45.7% share of Middle East & Africa lung cancer screening market in 2022, amassing US$ 8.00 million. It is projected to garner US$ 14.13 million by 2030 to expand at 7.4% CAGR during 2022–2030.

Based on age group, the Middle East & Africa lung cancer screening market is segmented into 50 and Older and Below 50. The 50 and older segment held 88.8% share of Middle East & Africa lung cancer screening market in 2022, amassing US$ 15.55 million. It is projected to garner US$ 26.55 million by 2030 to expand at 6.9% CAGR during 2022–2030.

Based on end user, the Middle East & Africa lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment held 50.2% share of Middle East & Africa lung cancer screening market in 2022, amassing US$ 8.79 million. It is projected to garner US$ 14.64 million by 2030 to expand at 6.6% CAGR during 2022–2030.

Based on country, the Middle East & Africa lung cancer screening market has been categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that the Rest of Middle East & Africa captured 42.3% share of Middle East & Africa lung cancer screening market in 2022. It was assessed at US$ 7.41 million in 2022 and is likely to hit US$ 12.38 million by 2030, exhibiting a CAGR of 6.6% during 2022–2030.      

Key players operating in the Middle East & Africa lung cancer screening market are Nuance Communications Inc, GE HealthCare, Medtronic, Canon Inc, Koninklijke Philips NV, and Siemens AG, Inc among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com